Status: Not yet recruiting
A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma
A single-arm clinical study on the efficacy and safety of the novel oncolytic virus Ad-TD-nsIL12 combined with PD-1 inhibitors in the treatment of recurrent high-grade glioma
Participants needed: 15
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Beijing Bio-Targeting Therapeutics Technology Co., LtdUpdated: Jul 14, 2026Locations: 1
Eligibility criteria
Willing and able to provide written informed consent for the study [+6]
Received treatment with any other unmarketed investigational drug within 4 weeks... [+12]